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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYThe CNS contains many diverse neuronal subtypes, and most neurological diseases target specific subtypes. However, the mechanism of
neuronal subtype specificity of disease phenotypes remains elusive. Although in vitro diseasemodels employinghumanpluripotent stem
cells (PSCs) have great potential to clarify the association of neuronal subtypes with disease, it is currently difficult to compare various
PSC-derived subtypes. This is due to the limited number of subtypes whose induction is established, and different cultivation protocols
for each subtype. Here, we report a culture system to control the regional identity of PSC-derived neurons along the anteroposterior (A-P)
and dorsoventral (D-V) axes. This systemwas successfully used to obtain various neuronal subtypes based on the same protocol. Further-
more, we reproduced subtype-specific phenotypes of amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD) by comparing the
obtained subtypes. Therefore, our culture system provides new opportunities for modeling neurological diseases with PSCs.INTRODUCTION
Modeling human diseases with pluripotent stem cells
(PSCs), including embryonic stem cells (ESCs) and induced
PSCs (iPSCs), has remarkable potential to generate new in-
sights into understanding disease pathogenesis and to
open up new avenues for effective therapies. In particular,
modeling neurological diseases is of great interest given
that it is difficult to obtain patient-derived neural cells or
tissues because of the limited accessibility to the brain.
Indeed, ESCs and iPSCs derived from patients have been
used to study several neurological diseases, including
amyotrophic lateral sclerosis (ALS; Dimos et al., 2008;
Egawa et al., 2012), Alzheimer’s disease (AD; Israel et al.,
2012; Kondo et al., 2013; Yagi et al., 2011), Parkinson’s dis-
ease (Devine et al., 2011; Imaizumi et al., 2012; Nguyen
et al., 2011), schizophrenia (Brennand et al., 2011; Bundo
et al., 2014; Hook et al., 2014), epilepsy (Higurashi et al.,
2013; Jiao et al., 2013; Liu et al., 2013), and Rett syndrome
(Andoh-Noda et al., 2015; Marchetto et al., 2010). Because
most neurological diseases affect one or more specific
lesion area(s), PSCs were differentiated into corresponding
neuronal subtypes in such studies (Imaizumi and Okano,
2014; Marchetto and Gage, 2012; Mattis and Svendsen,
2011; Okano and Yamanaka, 2014). However, these ap-
proaches cannot procure the mechanism of subtype speci-
ficity of disease phenotypes; that is, why some neuronal
subtypes are selectively damaged whereas others evade
pathogenesis.
To clarify the mechanism of subtype specificity, it is
necessary to compare phenotypes between disease-suscep-1010 Stem Cell Reports j Vol. 5 j 1010–1022 j December 8, 2015 j ª2015 Thtible and -insusceptible neuronal subtypes. Nonetheless,
this approach has not been developed to date for two rea-
sons. First, only a few neuronal subtypes can be success-
fully induced from PSCs. Second, each previously reported
protocol to induce specific subtypes varies in its cultivation
procedures, giving rise to variability between protocols in
efficiency, maturity, and culture-afflicted stress and pre-
venting a direct comparison across different neuronal
subtypes.
Here we addressed these problems by focusing on control
of the regional identity of PSC-derived neural progenitors
and neurons. The developing neural tube is subdivided
into distinct regions along the anteroposterior (A-P) and
dorsoventral (D-V) axes, and each region produces a spe-
cific subtype of neurons (Kiecker and Lumsden, 2012).
Namely, neuronal subtype specification in the neural
tube is determined in a region-specific manner. If the
regional identity of PSC-derived neurons could be regu-
lated at will based on the same protocol, then any desired
subtypes could be induced with the same efficiency and
under the same culture conditions. A protocol permitting
such regulation would enable the reproduction of disease
phenotypes in any given brain region and also the compar-
ison of phenotypes between different neuronal subtypes.
In this study, we report a robust method to control the
regional identity of PSC-derived neural progenitors and
neurons based on a single protocol. To do so, Wnt, retinoic
acid (RA), and sonic hedgehog (Shh) signaling were modu-
lated to manipulate the A-P and D-V identities of neural
progenitors. Regional identity was maintained throughout
neural differentiation, generating a variety of neuronale Authors
Figure 1. Strategy for Defining the
Regional Identity of PSC-Derived Neural
Progenitors
(A) Schematic of the strategy employed
for the manipulation of regional identity.
Wnt signaling was modulated by using the
porcupine inhibitor IWP-2 and the GSK3b
inhibitor CHIR. Tel, telencephalon; Di,
diencephalon; Mid, midbrain; Hind, hind-
brain; S.C., spinal cord.
(B) Overview of the culture protocol.
Patterning factors (IWP-2, CHIR, RA, Shh,
and purmorphamine) were added during
neurosphere formation.subtypes, including cortical projection neurons, cortical in-
terneurons, midbrain dopaminergic neurons, hindbrain
serotonergic neurons, spinal cord sensory interneurons,
and spinal cordmotor neurons. Finally, we compared these
neuronal subtypes and detected ventral spinal cord-specific
neurite swellings in ALS iPSCs and forebrain-specific
accumulation of phosphorylated tau (p-tau) in AD iPSCs.
Therefore, this culture system could be a useful tool to
approach the mechanism of subtype specificity of neuro-
logical disease phenotypes.RESULTS
Strategy for Defining the Regional Identity of
PSC-Derived Neural Progenitors
BecauseWnt, RA, and Shh signaling are involved in the for-
mation of the A-P andD-Vaxes during neural development
(Briscoe and Ericson, 2001; Marshall et al., 1992; Nord-
stro¨m et al., 2002), we explored the possibility that these
patterning signaling molecules might have analogous ef-
fects in neural cells differentiated from PSCs. We hypothe-
sized that the A-P identity (ranging from the telencephalon
to the spinal cord) can be controlled by regulatingWnt and
RA signaling and that the D-V identity can be controlled
similarly by regulating Shh signaling (Figure 1A). To eval-
uate this hypothesis, we induced neural progenitors
derived from ESCs (KhES-1; Suemori et al., 2006) by using
the neurosphere culture system (modified from Chaddah
et al., 2012) and treated the cells with modulators of
these patterning signaling pathways during neurosphere
formation (Figure 1B). The modulators included the
porcupine inhibitor IWP-2 (a Wnt antagonist; Chen
et al., 2009), the glycogen synthase kinase (GSK) 3b inhib-
itor CHIR99021 (a Wnt agonist, referred to hereafter as
CHIR; Ring et al., 2003), RA, Shh protein, and the Smo re-
ceptor agonist purmorphamine (a Shh agonist; Sinha and
Chen, 2006). Although the diameter of the neurospheres
was increased by treatment with CHIR and RA, each of
the experimental conditions was able to generate neuro-Stem Cell Repspheres (Figures S1A and S1B). Moreover, the patterning
factors did not influence the number of neurospheres
generated (Figure S1C), and the neural progenitor marker
NESTIN was expressed similarly under all conditions (Fig-
ure S1D). These results indicate that neural induction is un-
affected by Wnt, RA, or Shh signaling.Modulation of the A-P Identity of PSC-Derived Neural
Progenitors by Wnt and RA Signaling
We next examined the expression of A-P markers (Fig-
ure 2A) in ESC-derived neurospheres by qRT-PCR (Fig-
ure 2B). IWP-2-treated neurospheres expressed high
levels of the forebrain markers FOXG1 and SIX3 (Oliver
et al., 1995; Xuan et al., 1995). The expression levels
of the forebrain/midbrain markers OTX1 and OTX2
(Simeone et al., 1992) were highest in untreated neuro-
spheres. The low expression level of OTX1 in IWP-2-
treated neurospheres agrees with the observation that
this gene is not expressed in the anterior-most region of
the forebrain (Shimamura et al., 1997). EN1, which is ex-
pressed in the midbrain and the anterior hindbrain
(Hanks et al., 1995), was highly expressed in neurospheres
treated with CHIR at concentrations of 0.5 and 1 mM.
HOXB4 and HOXC4, markers of the posterior hindbrain
and the spinal cord (Hunt et al., 1991), were expressed pri-
marily in cultures exposed to 3 mM CHIR, and their
expression levels were enhanced further by the addition
of RA. These results indicate that the posteriorization of
neural progenitors is driven by activation of the Wnt
and RA signaling pathways.
The regulation of marker expression correlating with the
A-P axis was also confirmed by immunocytochemical anal-
ysis for the FOXG1, OTX1, and HOXB4 proteins (Fig-
ure 2C). Furthermore, we confirmed the robustness of our
protocol by using the 201B7 and 253G1 iPSC lines (Naka-
gawa et al., 2008; Takahashi et al., 2007). In both of
these iPSC lines, the expression levels of the A-P markers
in the neurospheres were similar to those in ESC-derived
neurospheres (Figure S2). These results suggest that theorts j Vol. 5 j 1010–1022 j December 8, 2015 j ª2015 The Authors 1011
Figure 2. A-P Patterning by Modifying Wnt and RA Signaling
(A) Expression of A-P markers in the neural tube in vivo.
(B) qRT-PCR analysis of neurospheres for A-P marker expression (n = 3 independent experiments, mean ± SEM). Activation of Wnt and RA
signaling posteriorized the neurospheres, whereas blockade of Wnt signaling anteriorized the neurospheres.
(C) Immunocytochemical analysis of neurospheres for A-P markers. The frequency of neurospheres containing immunopositive cells is
shown as the percentage of total neurospheres (n = 3 independent experiments, mean ± SEM). A-P patterning was also confirmed at the
protein level. Scale bar, 50 mm).
See also Table S1.A-P identity of PSC-derived neural progenitors can be
controlled by IWP-2, CHIR, and RA during neurosphere
formation.
Control of the D-V Identity of PSC-Derived Neural
Progenitors by Shh Signaling
In addition to the A-P identity, we next attempted to con-
trol the D-V identity by modulating Shh signaling. We hy-
pothesized that neural progenitors derived from PSCs are
dorsalized in the absence of Shh and that the activation
of Shh signaling ventralizes neural progenitors with no in-
fluence on the A-P identity. To address this hypothesis, we
assessed the expression levels of D-V makers in neuro-
spheres by qRT-PCR analysis with the addition of Shh
protein and purmorphamine (termed the ‘‘+Shh’’ group)
(Figures 3A and 3B). We used these two Shh activators
simultaneously because a previous report has demon-
strated that co-treatment with Shh protein and purmorph-
amine was greatly superior to high concentrations of either
of the two alone (Maroof et al., 2013). Other neurospheres1012 Stem Cell Reports j Vol. 5 j 1010–1022 j December 8, 2015 j ª2015 Threceived no exogenous ventralizing factors (termed the
‘‘Shh’’ group).
The D-V markers PAX6, PAX7, NKX2.1, and NKX2.2 are
differentially expressed in vivo according to A-P and D-V
positions (Figure 3A). PAX6 is expressed dorsally in the
forebrain, and the expression pattern also covers both the
dorsal and the ventral portions of the posterior hindbrain
and the spinal cord (Ericson et al., 1997; Osumi et al.,
1997; Takahashi and Osumi, 2002; Walther and Gruss,
1991). In contrast, themidbrain and the anterior hindbrain
lack PAX6 expression (with the exception of the rhombic
lip) (Engelkamp et al., 1999; Schwarz et al., 1999; Swanson
et al., 2005; Yamasaki et al., 2001). PAX7 is expressed
throughout the dorsal part of the neural tube except for
the anterior forebrain, where this gene is expressed only
in the small dorsal-most region (Matsunaga et al., 2001).
NKX2.1 marks the ventral forebrain (Qiu et al., 1998),
whereas NKX2.2 is expressed ventrally throughout the
A-P axis (Shimamura et al., 1995). Consistent with the
in vivo expression patterns of these genes, PAX6was highlye Authors
Figure 3. D-V Patterning by Treatment with Shh
(A) Expression of D-V markers in the neural tube. The dashed line indicates the alar-basal boundary.
(B) qRT-PCR analysis of neurospheres for D-V marker expression (n = 3 independent experiments, mean ± SEM). Neurospheres not treated
with Shh showed a dorsal identity, whereas Shh treatment ventralized the neurospheres.
(C and D) Immunocytochemical analysis of neurospheres for PAX6/NKX2.1 (C) and PAX6/NKX2.2 (D). The frequency of neurospheres
containing immunopositive cells is shown as the percentage of total neurospheres (n = 3 independent experiments, mean ± SEM). D-V
patterning was also confirmed at the protein level. Scale bars, 50 mm.
See also Table S1.expressed in neurospheres with forebrain characteristics
(i.e., IWP-2-treated and untreated neurospheres) in
the Shh group as well as those with the characteristics
of the posterior hindbrain and the spinal cord (i.e.,
CHIR3+RA-treated neurospheres). Only the latter main-
tained PAX6 expression after Shh activation. Meanwhile,
PAX7 was upregulated in the Shh group, except under
the IWP-2-treated condition, whereas PAX7 expression
was low under all conditions in the +Shh group. NKX2.1
was expressed primarily in neurospheres with forebrain
characteristics (IWP-2-treated and untreated) in the +Shh
group. The expression of NKX2.2 was generally high in
the +Shh group. The relatively low expression level of
NKX2.2 in neurospheres with posterior characteristics in
the +Shh group agreeswith the fact thatNKX2.2 expression
is initially only seen in the anterior part of the neural tube
and then gradually extends to the spinal cord (Shimamura
et al., 1995).
The control of the D-V axis shown by qRT-PCR anal-
ysis was also confirmed by immunocytochemical anal-
ysis for the PAX6, NKX2.1, and NKX2.2 proteins (Figures
3C and 3D). Moreover, D-V regulation was reproduced
readily in the iPSC lines (Figure S2). Our results
indicate that the D-V identity of PSC-derived neural pro-
genitors can be controlled without perturbing the A-P
identity.Stem Cell RepRecapitulation of Telencephalic D-V Patterning
To further confirm the D-V control, we examined the
expression of telencephalon-specific D-V markers (Fig-
ure 4A). EMX1/2 and DLX2 are confined to the dorsal and
the ventral telencephalon, respectively (with the exception
of small diencephalic regions) (Porteus et al., 1991; Si-
meone et al., 1992). Although the proneural genes NGN2
and ASCL1 are expressed in various regions of the neural
tube, a D-V bias in their expression is clearly observed in
the telencephalon (Fode et al., 2000). EMX1/2 and NGN2
were significantly upregulated in IWP-2-treated neuro-
spheres without Shh activation. In contrast, the expression
ofDLX2 and ASCL1was increased by Shh activation. These
data provide additional evidence for the D-V control of
PSC-derived neural progenitors.
Differentiation of Neural Progenitors into Specific
Neuronal Subtypes in Accordance with Regional
Identity
To investigate whether the regional identity of neural pro-
genitors was retained upon differentiation into neurons,
neurospheres were subjected to a neural differentiation
protocol (Figure 1B). Our protocol predominantly pro-
duced neurons rather than astrocytes or oligodendrocytes
(Figure S3A). We examined the expression of synapse
markers and the intracellular calcium level during electricalorts j Vol. 5 j 1010–1022 j December 8, 2015 j ª2015 The Authors 1013
Figure 4. Telencephalic D-V Patterning
(A) Expression of D-V markers in the telencephalon. MGE, medial ganglionic eminence; LGE, lateral ganglionic eminence; POA, preoptic
area.
(B) qRT-PCR analysis of neurospheres for telencephalic D-V marker expression (n = 34 independent experiments; mean ± SEM; *p < 0.05,
**p < 0.01, ***p < 0.001; Student’s t test).field stimulation (Figures S3B–S3D). These results indicate
that neurons derived by our protocol were functional
regardless of the experimental conditions.
We determined the A-P identity of neurosphere-differen-
tiated neurons (Figure 5A). Neurons generated from IWP-2-
treated neurospheres expressed high levels of the forebrain
cortical neuronal marker TBR1 (Bulfone et al., 1995).
GATA3, expressed from the diencephalon to the hindbrain
(George et al., 1994), was upregulated at low CHIR concen-
trations (01 mM). LBX1, which marks dorsal neurons
in the hindbrain and the spinal cord (Jagla et al., 1995),
was highly expressed in neurons differentiated from
CHIR3+RA-treated neurospheres. These results imply that
neural progenitors retain their A-P identity in differenti-
ated neuronal cultures.
Wenext examined theD-V identity of differentiated neu-
rons (Figures 5B–5F). In the telencephalon, TBR1+ cortical
neurons are born dorsally, whereas the ventral area pro-
duces cortical interneurons, which is marked by LHX6
and LHX8 expression (Marı´n and Rubenstein, 2001). As ex-
pected, the expression level of TBR1 was elevated in neu-
rons generated from IWP-2-treated neurospheres and
decreased by activation of Shh signaling (Figures 5B and
5E). In contrast, LHX6 and LHX8were significantly upregu-
lated by Shh activation (Figure 5B). Dopaminergic and
serotonergic neurons are selectively derived from the
ventral portion of the midbrain and the hindbrain, respec-
tively (Goridis and Rohrer, 2002). Although the gene
expression of the dopamine-synthesizing enzyme TH did
not change significantly, that of LMX1A and FOXA2, mas-
ter transcriptional regulators of dopaminergic neuronal dif-
ferentiation (Andersson et al., 2006; Ferri et al., 2007), was
upregulated markedly by Shh activation under the 0.5 mM
CHIR-treated condition (Figure 5C; Figure S4A).We also de-
tected high expression of the serotonergic neuronalmarker
PET1 (Hendricks et al., 1999) concomitantly with a small
population of cells thatwere immunopositive for serotonin
(Figure 5C; Figure S4C). Furthermore, VMAT2 and AADC,1014 Stem Cell Reports j Vol. 5 j 1010–1022 j December 8, 2015 j ª2015 Thmarkers for both dopaminergic and serotonergic neurons
(Flames and Hobert, 2011), were upregulated (Figure S4A).
LHX9, which marks d1 neurons in the dorsal spinal cord
(Liem et al., 1997), was highly expressed in neurons gener-
ated from CHIR3+RA-treated neurospheres, whereas the
expression of HB9, which marks motor neurons in the
ventral spinal cord (Arber et al., 1999), was elevated by ven-
tralization via Shh activation (Figures 5D and 5F). CHT, an
additional spinal cord motor neuron marker that is essen-
tial for the uptake of choline into motor neurons (Okuda
et al., 2000), was also upregulated (Figure S4B).
Finally, we tested whether neural crest-derived peripheral
neurons were induced. The peripheral neuron marker Pe-
ripherin (Escurat et al., 1990) was not detected under almost
all conditions. However, approximately 20% of neurons
were immunopositive for this marker under the CHIR3+RA-
treated and CHIR3+RA+Shh-treated conditions. Under the
CHIR3+RA-treated condition, BRN3A, an additional periph-
eral neuronmarker (Fedtsova and Turner, 1995),was also ex-
pressed in a portion of Peripherin+ neurons (Figure S4D).
Given that neural crest cells originate from the dorsal-most
region of the neural tube (Knecht and Bronner-Fraser,
2002), these results are consistent with their dorsal identity.
Under the CHIR3+RA+Shh-treated condition, however,
Peripherin+ neurons expressed the motor neuron marker
SMI-32 (Carriedo et al., 1996). This result is consistent with
the fact that Peripherin is expressed not only in peripheral
neurons but also in spinal cord motor neurons (Escurat
et al., 1990). In summary, both the A-P and D-V identities
acquired in the neural progenitor stage were maintained
throughout neuronal differentiation in culture, and neural
progenitors were able to differentiate into specific neuronal
subtypes in accordance with their regional identities.
Reproduction of Subtype-Specific Disease Phenotypes
In Vitro
In most neurological diseases, specific neuronal subtypes
are selectively impaired. For example, spinal cord motore Authors
Figure 5. Generation of Region-Specific
Neuronal Subtypes
(A) qRT-PCR analysis of neurosphere-
derived neurons for TBR1, GATA3, and LBX1
expression (n = 45 independent experi-
ments, mean ± SEM). A-P patterning was
maintained throughout neuronal differen-
tiation in vitro.
(BD) qRT-PCR analysis of neurosphere-
derived neurons for the expression of
neuronal subtype markers expressed in the
forebrain (B), the mid/hindbrain (C), and
the spinal cord (D) (n = 57 independent
experiments; mean ± SEM; *p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001; Stu-
dent’s t test). Neurospheres differentiated
into specific neuronal subtypes in accor-
dance with their regional identity.
(E and F) Immunocytochemical analysis of
neurosphere-derived neurons for TBR1 (E)
and HB9 (F). The frequency of immuno-
positive cells is shown as the percentage of
MAP2+ neurons (n = 3 independent experi-
ments, mean ± SEM). Scale bars, 50 mm.
See also Table S1.neurons are selectively damaged in ALS (Bruijn et al.,
2004), and forebrain cortical neurons are preferentially
affected in AD (Braak and Braak, 1991; Morrison and
Hof, 1997; Thal et al., 2002). Although this subtype spec-Stem Cell Repificity probably plays an important role in pathology, its
mechanism remains to be elucidated. Particularly in
PSC-based disease models, most previous reports have
focused only on the disease-susceptible neuronal subtype,orts j Vol. 5 j 1010–1022 j December 8, 2015 j ª2015 The Authors 1015
Figure 6. Reproduction of Subtype-Specific Disease Phenotypes In Vitro
(A) Representative images of neurites from PSC-derived neurons with the characteristics of the ventral spinal cord (CHIR3+RA+Shh-
treated). ALS iPSC-derived neurons exhibited swollen neurites (arrowheads). Scale bar, 10 mm.
(B) Quantification of neurons with neurite swellings (n = 3 independent experiments, mean ± SEM, ***p < 0.001, ANOVA with Tukey’s
test). ALS iPSC-derived neurons with the characteristics of the ventral spinal cord were remarkably damaged.
(C) Immunocytochemical analysis of AD iPSC-derived neurons with forebrain characteristics (IWP-2-treated). Accumulation of p-tau was
observed in the AD iPSC cultures (arrowhead). Scale bar, 50 mm.
(D) Higher-magnification images of the immunoreactive p-tau+ spots shown in (C). Scale bar, 10 mm.
(E) Quantification of p-tau+ spots (n = 3 independent experiments, mean ± SEM, *p < 0.05, ANOVA with Tukey’s test). Accumulation of
p-tau was increased in AD iPSC-derived neurons with forebrain characteristics.and other aspects of subtype specificity have yet to be
explored.
Our first aim was to test whether disease subtype speci-
ficity can be recapitulated in vitro by using PSCs. We
derived neurons from disease-specific iPSC lines via our
protocol described above. Here we used ALS and AD iPSC
lines carrying TARDBPM337V and PSEN1A246E/PSEN2N141I
mutations, respectively (Egawa et al., 2012; Yagi et al.,
2011), and the control of regional identity was confirmed
in neurospheres derived from each iPSC line (Figure S5).
In the ALS iPSC-derived neurons, neurite swellings were
observed preferentially in neurons with the characteristics
of the ventral spinal cord generated from CHIR3+RA+Shh-
treated neurospheres (Figures 6A and 6B). In contrast,
neurons with other regional identities rarely exhibited
swellings. Because neurite swellings (or ‘‘spheroids’’) are a
feature of neuronal cell dysfunction in ALS (Delisle and
Carpenter, 1984), these observations suggest that ventral
spinal cord-specific phenotypes of ALS were recapitulated1016 Stem Cell Reports j Vol. 5 j 1010–1022 j December 8, 2015 j ª2015 Thsuccessfully in our system. Next, we tried to demonstrate
motor neuron specificity among the ventral spinal cord
subtypes by labeling motor neurons with the fluorescence
protein (Venus) reporter under control of the HB9 pro-
moter. However, the cells showed fluorescence labeling of
only the soma and proximal neurites, probably because
of weak intracellular diffusion of the Venus protein. Conse-
quently, we failed to identify neurite swellings distal to the
soma in HB9-Venus-positive neurons (data not shown).
Therefore, currently, we cannot eliminate the possibility
that subtypes other than motor neurons in the ventral spi-
nal cord were also affected by neurite swellings. Indeed,
several recent reports indicate that spinal cord interneu-
rons are implicated in ALS pathology (reviewed in Turner
and Kiernan, 2012).
In AD iPSC-derived neurons, we found spot-like accumu-
lations of p-tau (Figures 6C and 6D). The number of p-tau+
spots increased in neurons with forebrain characteristics
generated from IWP-2-treated neurospheres comparede Authors
with the CHIR3+RA condition corresponding to the spinal
cord (Figure 6E; Figure S6A). To eliminate the possibility
that the addition of CHIR during the neurosphere stage
led to inhibition of GSK3b-mediated tau phosphorylation
in the differentiation stage, we next measured GSK3b
activity in differentiated neurons by quantifying nuclear
b-catenin intensity. We confirmed that b-catenin intensity
remained relatively constant under all conditions and that
residual CHIR had no effect on tau phosphorylation in the
differentiation stage (Figure S6B). These results indicate
that a characteristic feature of AD pathology, i.e., p-tau
accumulation, was reproduced in a region-specific manner.
Taken together, our findings show that the subtype speci-
ficity of neurological disease phenotypes can be modeled
in vitro by defining the regional identity of PSC-derived
neural progenitors and neurons.DISCUSSION
In this study, we established a culture system for control-
ling the regional identity of PSC-derived neural progenitors
and neurons based on an identical protocol. Simple treat-
ment with three factors, IWP-2, CHIR, and RA, effectively
patterned the A-P identity, ranging from the telencephalon
to the spinal cord. In addition, Shh activation converted
the D-V identity from dorsal into ventral without perturb-
ing the A-P identity. Furthermore, subtype-specific ALS and
AD phenotypes were reproduced in vitro by using the
described protocol.
Our findings are consistent with previous reports
demonstrating that the graded signaling activities of
Wnt/RA and Shh establish the A-P and D-V axes in vivo.
Also noteworthy is that our study shows that this model
for early neural patterning, which is proposed mostly
from work on Xenopus, chicks, and mice, can be applied
to human development. Because in vivo experiments
of the human embryo are ethically challenging and
technically difficult, our culture system now provides
novel opportunities to uncover the mechanism of neural
patterning in humans.
A remaining issue regarding our present culture system
is the ability to recapitulate the environment after regional
specification. In some neuronal subtypes, additional sig-
nals are needed for further specification, maturation, and
maintenance. When cells migrate from their birthplace
or if they project to distant targets, they often receive
such signals from cells with different regional identity.
Such additional signals cannot be recapitulated in our
present culture system. In the case of midbrain dopami-
nergic neurons, for example, transforming growth factor
b (TGF-b) expressed in their projection targets is necessary
for their maintenance (Poulsen et al., 1994). Dopami-Stem Cell Repnergic neurons in our culture did not express late-stage
markers such as PITX3 and DAT, probably because of the
lack of such additional signals (data not shown). In addi-
tion to treatment with signaling modulators, co-culturing
with cells of the destination of migration or cells of the
projection targets would be a promising approach to over-
come this issue.
Specific brain regions are preferentially damaged in most
neurological diseases, whereas regions other than the
lesioned area remain relatively unaffected. For this reason,
the differentiation of patient-derived iPSCs into specific
neuronal subtypes representing the lesion site is a valuable
approach for modeling human neurological diseases (Imai-
zumi and Okano, 2014; Okano and Yamanaka, 2014). The
current investigation reproduced p-tau accumulation as an
AD phenotype by endowing neurons with forebrain char-
acteristics. On the other hand, a previous report using the
same iPSC clones did not detect such a phenotype, prob-
ably because of the induction of inappropriate subtypes
(Yagi et al., 2011). These results highlight the importance
of correct neuronal subtype specification in reproducing
neurological disease phenotypes with PSCs.
Some investigators have reported the directed differenti-
ation of PSCs into a limited number of neuronal subtypes,
including midbrain dopaminergic neurons and spinal cord
motor neurons (Kriks et al., 2011; Li et al., 2005). Given
that each differentiation protocol is overly optimized for
a particular subtype, the protocol in question cannot be
readily applied to additional neuronal subtypes. Neverthe-
less, our culture system theoretically enables the differenti-
ation of PSCs into all neuronal subtypes, making it possible
to efficiently generate subtypes whose induction fromPSCs
has been difficult.
Also, as emphasized above, our culture system is based on
the same protocol to obtain neuronal subtypes with equiv-
alent efficiency and under the same general culture condi-
tions (with the exception of the modulation of different
signaling cascades). Therefore, our method allows compar-
ative analysis of a variety of neuronal subtypes, whereas
earlier investigations on disease modeling have focused
only on selectively affected subtypes. Moreover, other in-
vestigators have reported that the modulation of Wnt
signaling can direct the regional identity of PSC-derived
neurons in amanner similar to that observed in our culture
system. Nevertheless, a parallel analysis of disease pheno-
types between neurons with different regional identities
was not performed in these studies (Kirkeby et al., 2012;
Moya et al., 2014). To fully understand the mechanism of
disease pathology and progression, one must investigate
not only the manner in which specific neuronal subtypes
are affected but also howother subtypes remain unaffected.
In the case of genetic diseases, neural subtype specificity of
disease phenotypes is not necessarily accounted for by theorts j Vol. 5 j 1010–1022 j December 8, 2015 j ª2015 The Authors 1017
expression pattern of the responsible genes. For example,
some mutations in TARDBP, which is globally expressed
across the entire brain, cause motor neuron-selective
degeneration (Kabashi et al., 2008, 2010; Sephton et al.,
2010). Similarly, although PSEN1 and PSEN2 show
widespread expression in the brain, their mutations pre-
dominantly affect forebrain neurons (Rogaev et al., 1995;
Sherrington et al., 1995). However, the mechanism of
neuronal subtype specificity of these disease phenotypes
is unclear. Our culture system may permit investigations
toward filling in the gaps in this knowledge base.
We do not yet know themechanism of neuronal subtype
specificity of various neurological disease phenotypes.
Identification of factors enforcing pathogenesis in dis-
ease-susceptible subtypes or evading pathogenesis in insus-
ceptible subtypes will help to clarify this. Regardless, our
culture system will undoubtedly allow new insights into
modeling neurological diseases with PSCs.EXPERIMENTAL PROCEDURES
Culture of Undifferentiated ESCs and iPSCs
The human ESC (hESC) line KhES-1 (Suemori et al., 2006), the con-
trol human iPSC (hiPSC) lines 201B7 and 253G1 (Nakagawa et al.,
2008; Takahashi et al., 2007), the ALS iPSC line A3411 (Egawa et al.,
2012), and the AD iPSC lines PS1-2 and PS2-1 (Yagi et al., 2011)
were cultured on mitomycin C-treated SNL murine fibroblast
feeder cells in standard hESC medium (DMEM/F12, Sigma)
containing 20% KnockOut serum (KSR) replacement (Life Tech-
nologies), 0.1 mM non-essential amino acids (Sigma), 0.1 mM
2-mercaptoethanol (Sigma), and 4 ng/ml fibroblast growth factor
2 (FGF-2) (PeproTech)) in an atmosphere containing 3% CO2.
hESCs were used in accordancewith the guidelines regarding the
utilization of hESCs with approval from theMinistry of Education,
Culture, Sports, Science, and Technology (MEXT) of Japan and the
Keio University School of Medicine Ethics Committee. All experi-
mental procedures for iPSCs derived from patients were approved
by the Keio University School of Medicine Ethics Committee
(approval no. 20080016).Neuronal Induction
Neuronal induction of hESCs/iPSCs was performed as described
previously (Chaddah et al., 2012), with slight modifications.
Briefly, hESCs/iPSCs were pretreated for 6 days with 3 mM
SB431542 (Tocris), 150 nM LDN193189 (StemRD), and 3 mM
CHIR99021 (Stemgent). They were then dissociated and seeded
at a density of 10 cells/ml in medium hormonemix (MHM) (Okada
et al., 2004, 2008; Shimazaki et al., 2001) with selected growth
factors and inhibitors under conditions of 4% O2/5% CO2. The
growth factors and inhibitors included 10 ng/ml human leukemia
inhibitory factor (LIF) (Nacalai Tesque), 20 ng/ml FGF-2, 13 B27
supplement (Invitrogen), 2 mM SB431542, and 10 mM Y-27632
(Calbiochem).
Defining the day on which neurosphere culture was started as
day 0, the following additives were included in the neurosphere1018 Stem Cell Reports j Vol. 5 j 1010–1022 j December 8, 2015 j ª2015 Thculture: 2 mM IWP-2 (Sigma), 0.5–3 mM CHIR99021, and 1 mM
RA (Sigma) from days 0–12 and 100 ng/ml Shh-C24II (R&D Sys-
tems) and 1 mM purmorphamine (Calbiochem) from days 2–12.
On day 12, neurospheres were replated en bloc on dishes coated
with poly-ornithine and laminin and cultured under conditions
of 5% CO2. The medium was changed to MHM supplemented
with 13 B27 and 1 mM DAPT (Sigma). DAPT was excluded in the
AD phenotype experiments.
qRT-PCR
Total RNA was isolated with the RNeasy mini kit (QIAGEN) with
DNase I treatment, and cDNAwas prepared by using a ReverTraAce
qPCR RT kit (Toyobo). The qRT-PCR analysis was performed with
SYBR premix Ex TaqII (Takara Bio) on a ViiA 7 real-time PCR system
(Applied Biosystems). Values were normalized to ACTB. Reactions
were carried out in duplicate, and data were analyzed by using
the comparative (DDCt) method. Relative expression levels are
presented as geometric means ± geometric SEM. The primer sets
used in these experiments are listed in Table S2.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde for 15 min at room
temperature and then washed three times with PBS. After incu-
bating with blocking buffer (PBS containing 5% normal fetal
bovine serum and 0.3% Triton X-100) for 1 hr at room tempera-
ture, the cells were incubated overnight at 4C with primary anti-
bodies diluted with blocking buffer. We used blocking buffer
without TritonX-100 for O4 staining and buffer with 0.03%Triton
X-100 for Synaptotagmin and VAMP2 staining. Details of the pri-
mary antibodies and the dilution conditions are listed in Table
S3. The cells were again washed three times with PBS and incu-
bated with secondary antibodies conjugated with Alexa Fluor
488, Alexa Fluor 555, or Alexa Fluor 647 (Life Technologies) and
Hoechst33342 (Dojindo Laboratories) for 1 hr at room tempera-
ture. After washing three times with PBS and once with distilled
water, samples were mounted on slides and examined by using
a LSM-710 confocal laser-scanning microscope (Carl Zeiss). For
anti-NKX2.2 antibody staining, biotinylated secondary antibodies
(Jackson ImmunoResearch Laboratories) were used after exposure
to 1% H2O2 for 30 min at room temperature to inactivate endoge-
nous peroxidase. The signals were then enhanced by using the
Vectastain ABC kit (Vector Laboratories), followed by the TSA
fluorescence system (PerkinElmer).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, six figures, and three tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2015.10.005.
AUTHOR CONTRIBUTIONS
K. Imaizumi, W.A., and H.O. conceived and designed the project.
K. Imaizumi and T.S. performed the experiments. K. Ibata and
M.Y. performed the calcium imaging assays. K. Imaizumi and K.F.
established the nuclear b-catenin intensity assay. K. Imaizumi,
W.A., and H.O. interpreted the data and wrote the manuscript.e Authors
ACKNOWLEDGMENTS
We are grateful to Y. Okada (Aichi Medical University) and T. Mat-
sumoto (Ajinomoto) for technical assistance, helpful advice, and
discussions; T. Abe (Keio University) for statistical analysis; and
all members of the H.O. laboratory for encouragement and kind
support. We also thank Y. Okada for the HB9-Venus reporter, M.
Itakura (KitasatoUniversity) for antibodies, N. Nakatsuji andH. Su-
emori (Kyoto University) for hESC clones, S. Yamanaka andM. Na-
kagawa (KyotoUniversity) for hiPSC clones (253G1 and 201B7), H.
Inoue (KyotoUniversity) for ALS iPSC clones, andN. Suzuki andD.
Ito (Keio University) for AD iPSC clones. This work was supported
by funding from the Project for the Realization of Regenerative
Medicine and Support for Core Institutes for iPS Cell Research
from theMinistry of Education, Culture, Sports, Science, and Tech-
nology of Japan (MEXT) (to H.O. and W.A.); the Research Center
Network for Realization Research Centers/Projects of Regenerative
Medicine (the Program for Intractable Disease Research utilizing
disease-specific iPS Cells) from the Japan Science and Technology
Agency (JST) and the Japan Agency for Medical Research and
Development (AMED) (to H.O.); Scientific Research on Innovative
Area, aMEXTGrant-in-Aid Project FY2014-2018 ‘‘Brain Protein Ag-
ing and Dementia Control’’ (to H.O.); New Energy and Industrial
Technology Development Organization (to H.O. and W.A.); and
the Keio University Medical Science Fund (to K. Imaizumi). H.O.
is a paid scientific advisory board member for SanBio Co., Ltd.
Received: June 3, 2015
Revised: October 8, 2015
Accepted: October 8, 2015
Published: November 5, 2015REFERENCES
Andersson, E., Tryggvason, U., Deng, Q., Friling, S., Alekseenko, Z.,
Robert, B., Perlmann, T., and Ericson, J. (2006). Identification of
intrinsic determinants of midbrain dopamine neurons. Cell 124,
393–405.
Andoh-Noda, T., Akamatsu, W., Miyake, K., Matsumoto, T., Yama-
guchi, R., Sanosaka, T., Okada, Y., Kobayashi, T., Ohyama, M., Na-
kashima, K., et al. (2015). Differentiation of multipotent neural
stem cells derived from Rett syndrome patients is biased toward
the astrocytic lineage. Mol. Brain 8, 31.
Arber, S., Han, B., Mendelsohn, M., Smith, M., Jessell, T.M., and
Sockanathan, S. (1999). Requirement for the homeobox gene Hb9
in theconsolidationofmotorneuron identity.Neuron23, 659–674.
Braak, H., and Braak, E. (1991). Neuropathological stageing of
Alzheimer-related changes. Acta Neuropathol. 82, 239–259.
Brennand, K.J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N.,
Sangar, S., Li, Y., Mu, Y., Chen, G., Yu, D., et al. (2011). Modelling
schizophrenia using human induced pluripotent stem cells.
Nature 473, 221–225.
Briscoe, J., and Ericson, J. (2001). Specification of neuronal fates in
the ventral neural tube. Curr. Opin. Neurobiol. 11, 43–49.
Bruijn, L.I., Miller, T.M., and Cleveland, D.W. (2004). Unraveling
the mechanisms involved in motor neuron degeneration in ALS.
Annu. Rev. Neurosci. 27, 723–749.Stem Cell RepBulfone, A., Smiga, S.M., Shimamura, K., Peterson, A., Puelles, L.,
and Rubenstein, J.L. (1995). T-brain-1: a homolog of Brachyury
whose expression defines molecularly distinct domains within
the cerebral cortex. Neuron 15, 63–78.
Bundo, M., Toyoshima, M., Okada, Y., Akamatsu, W., Ueda, J.,
Nemoto-Miyauchi, T., Sunaga, F., Toritsuka, M., Ikawa, D., Kakita,
A., et al. (2014). Increased l1 retrotransposition in the neuronal
genome in schizophrenia. Neuron 81, 306–313.
Carriedo, S.G., Yin, H.Z., andWeiss, J.H. (1996).Motor neurons are
selectively vulnerable to AMPA/kainate receptor-mediated injury
in vitro. J. Neurosci. 16, 4069–4079.
Chaddah, R., Arntfield, M., Runciman, S., Clarke, L., and van der
Kooy, D. (2012). Clonal neural stem cells from human embryonic
stem cell colonies. J. Neurosci. 32, 7771–7781.
Chen, B., Dodge, M.E., Tang, W., Lu, J., Ma, Z., Fan, C.-W., Wei, S.,
Hao, W., Kilgore, J., Williams, N.S., et al. (2009). Small molecule-
mediated disruption ofWnt-dependent signaling in tissue regener-
ation and cancer. Nat. Chem. Biol. 5, 100–107.
Delisle, M.B., and Carpenter, S. (1984). Neurofibrillary axonal
swellings and amyotrophic lateral sclerosis. J. Neurol. Sci. 63,
241–250.
Devine, M.J., Ryten, M., Vodicka, P., Thomson, A.J., Burdon, T.,
Houlden, H., Cavaleri, F., Nagano, M., Drummond, N.J., Taan-
man, J.-W., et al. (2011). Parkinson’s disease induced pluripotent
stem cells with triplication of the a-synuclein locus. Nat. Com-
mun. 2, 440.
Dimos, J.T., Rodolfa, K.T., Niakan, K.K., Weisenthal, L.M., Mitsu-
moto, H., Chung, W., Croft, G.F., Saphier, G., Leibel, R., Goland,
R., et al. (2008). Induced pluripotent stem cells generated from pa-
tients with ALS can be differentiated into motor neurons. Science
321, 1218–1221.
Egawa, N., Kitaoka, S., Tsukita, K., Naitoh,M., Takahashi, K., Yama-
moto, T., Adachi, F., Kondo, T., Okita, K., Asaka, I., et al. (2012).
Drug screening for ALS using patient-specific induced pluripotent
stem cells. Sci. Transl. Med. 4, 145ra104.
Engelkamp, D., Rashbass, P., Seawright, A., and van Heyningen, V.
(1999). Role of Pax6 in development of the cerebellar system.
Development 126, 3585–3596.
Ericson, J., Rashbass, P., Schedl, A., Brenner-Morton, S., Kawakami,
A., van Heyningen, V., Jessell, T.M., and Briscoe, J. (1997). Pax6
controls progenitor cell identity and neuronal fate in response to
graded Shh signaling. Cell 90, 169–180.
Escurat, M., Djabali, K., Gumpel, M., Gros, F., and Portier, M.M.
(1990). Differential expression of two neuronal intermediate-
filament proteins, peripherin and the low-molecular-mass neurofi-
lament protein (NF-L), during the development of the rat.
J. Neurosci. 10, 764–784.
Fedtsova, N.G., and Turner, E.E. (1995). Brn-3.0 expression iden-
tifies early post-mitotic CNS neurons and sensory neural precur-
sors. Mech. Dev. 53, 291–304.
Ferri, A.L.M., Lin, W., Mavromatakis, Y.E., Wang, J.C., Sasaki, H.,
Whitsett, J.A., and Ang, S.L. (2007). Foxa1 and Foxa2 regulatemul-
tiple phases of midbrain dopaminergic neuron development in a
dosage-dependent manner. Development 134, 2761–2769.orts j Vol. 5 j 1010–1022 j December 8, 2015 j ª2015 The Authors 1019
Flames, N., and Hobert, O. (2011). Transcriptional control of the
terminal fate of monoaminergic neurons. Annu. Rev. Neurosci.
34, 153–184.
Fode, C., Ma, Q., Casarosa, S., Ang, S.L., Anderson, D.J., and
Guillemot, F. (2000). A role for neural determination genes in
specifying the dorsoventral identity of telencephalic neurons.
Genes Dev. 14, 67–80.
George, K.M., Leonard,M.W., Roth,M.E., Lieuw, K.H., Kioussis, D.,
Grosveld, F., and Engel, J.D. (1994). Embryonic expression and
cloning of the murine GATA-3 gene. Development 120, 2673–
2686.
Goridis, C., and Rohrer, H. (2002). Specification of catecholamin-
ergic and serotonergic neurons. Nat. Rev. Neurosci. 3, 531–541.
Hanks, M., Wurst, W., Anson-Cartwright, L., Auerbach, A.B., and
Joyner, A.L. (1995). Rescue of the En-1 mutant phenotype by
replacement of En-1 with En-2. Science 269, 679–682.
Hendricks, T., Francis, N., Fyodorov, D., and Deneris, E.S. (1999).
The ETS domain factor Pet-1 is an early and precise marker of cen-
tral serotonin neurons and interacts with a conserved element in
serotonergic genes. J. Neurosci. 19, 10348–10356.
Higurashi, N., Uchida, T., Lossin, C., Misumi, Y., Okada, Y., Aka-
matsu, W., Imaizumi, Y., Zhang, B., Nabeshima, K., Mori, M.X.,
et al. (2013). A human Dravet syndrome model from patient
induced pluripotent stem cells. Mol. Brain 6, 19.
Hook, V., Brennand, K.J., Kim, Y., Toneff, T., Funkelstein, L., Lee,
K.C., Ziegler, M., and Gage, F.H. (2014). Human iPSC neurons
display activity-dependent neurotransmitter secretion: aberrant
catecholamine levels in schizophrenia neurons. Stem Cell Reports
3, 531–538.
Hunt, P., Gulisano, M., Cook, M., Sham, M.H., Faiella, A., Wilkin-
son, D., Boncinelli, E., and Krumlauf, R. (1991). A distinct Hox
code for the branchial region of the vertebrate head. Nature 353,
861–864.
Imaizumi, Y., and Okano, H. (2014). Modeling human neurolog-
ical disorders with induced pluripotent stem cells. J. Neurochem.
129, 388–399.
Imaizumi, Y., Okada, Y., Akamatsu, W., Koike, M., Kuzumaki, N.,
Hayakawa, H., Nihira, T., Kobayashi, T., Ohyama, M., Sato, S.,
et al. (2012). Mitochondrial dysfunction associated with increased
oxidative stress and a-synuclein accumulation in PARK2 iPSC-
derived neurons and postmortem brain tissue. Mol. Brain 5, 35.
Israel, M.A., Yuan, S.H., Bardy, C., Reyna, S.M., Mu, Y., Herrera, C.,
Hefferan,M.P., VanGorp, S., Nazor, K.L., Boscolo, F.S., et al. (2012).
Probing sporadic and familial Alzheimer’s disease using induced
pluripotent stem cells. Nature 482, 216–220.
Jagla, K., Dolle´, P., Mattei, M.G., Jagla, T., Schuhbaur, B., Dretzen,
G., Bellard, F., and Bellard, M. (1995). Mouse Lbx1 and human
LBX1 define a novel mammalian homeobox gene family related
to the Drosophila lady bird genes. Mech. Dev. 53, 345–356.
Jiao, J., Yang, Y., Shi, Y., Chen, J., Gao, R., Fan, Y., Yao, H., Liao, W.,
Sun, X.F., and Gao, S. (2013). Modeling Dravet syndrome using
induced pluripotent stem cells (iPSCs) and directly converted
neurons. Hum. Mol. Genet. 22, 4241–4252.
Kabashi, E., Valdmanis, P.N., Dion, P., Spiegelman, D., McConkey,
B.J., Vande Velde, C., Bouchard, J.-P., Lacomblez, L., Pochigaeva,1020 Stem Cell Reports j Vol. 5 j 1010–1022 j December 8, 2015 j ª2015 ThK., Salachas, F., et al. (2008). TARDBP mutations in individuals
with sporadic and familial amyotrophic lateral sclerosis. Nat.
Genet. 40, 572–574.
Kabashi, E., Lin, L., Tradewell, M.L., Dion, P.A., Bercier, V., Bour-
gouin, P., Rochefort, D., Bel Hadj, S., Durham, H.D., Vande Velde,
C., et al. (2010). Gain and loss of function of ALS-relatedmutations
of TARDBP (TDP-43) cause motor deficits in vivo. Hum. Mol.
Genet. 19, 671–683.
Kiecker, C., and Lumsden, A. (2012). The role of organizers in
patterning the nervous system. Annu. Rev. Neurosci. 35, 347–367.
Kirkeby, A., Grealish, S., Wolf, D.A., Nelander, J., Wood, J., Lund-
blad, M., Lindvall, O., and Parmar, M. (2012). Generation of
regionally specified neural progenitors and functional neurons
from human embryonic stem cells under defined conditions.
Cell Rep. 1, 703–714.
Knecht, A.K., and Bronner-Fraser, M. (2002). Induction of the neu-
ral crest: a multigene process. Nat. Rev. Genet. 3, 453–461.
Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y.,
Imamura, K., Egawa, N., Yahata, N., Okita, K., et al. (2013).
Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes
associated with intracellular Ab and differential drug responsive-
ness. Cell Stem Cell 12, 487–496.
Kriks, S., Shim, J.-W., Piao, J., Ganat, Y.M., Wakeman, D.R., Xie, Z.,
Carrillo-Reid, L., Auyeung, G., Antonacci, C., Buch, A., et al.
(2011). Dopamine neurons derived fromhuman ES cells efficiently
engraft in animal models of Parkinson’s disease. Nature 480,
547–551.
Li, X.J., Du, Z.W., Zarnowska, E.D., Pankratz, M., Hansen, L.O.,
Pearce, R.A., and Zhang, S.C. (2005). Specification of motoneurons
from human embryonic stem cells. Nat. Biotechnol. 23, 215–221.
Liem, K.F., Jr., Tremml, G., and Jessell, T.M. (1997). A role for the
roof plate and its resident TGFbeta-related proteins in neuronal
patterning in the dorsal spinal cord. Cell 91, 127–138.
Liu, Y., Lopez-Santiago, L.F., Yuan, Y., Jones, J.M., Zhang, H.,
O’Malley, H.A., Patino, G.A., O’Brien, J.E., Rusconi, R., Gupta, A.,
et al. (2013). Dravet syndrome patient-derived neurons suggest a
novel epilepsy mechanism. Ann. Neurol. 74, 128–139.
Marchetto, M.C., and Gage, F.H. (2012). Modeling brain disease in
a dish: really? Cell Stem Cell 10, 642–645.
Marchetto, M.C.N., Carromeu, C., Acab, A., Yu, D., Yeo, G.W., Mu,
Y., Chen, G., Gage, F.H., and Muotri, A.R. (2010). A model for neu-
ral development and treatment of Rett syndrome using human
induced pluripotent stem cells. Cell 143, 527–539.
Marı´n, O., and Rubenstein, J.L. (2001). A long, remarkable journey:
tangential migration in the telencephalon. Nat. Rev. Neurosci. 2,
780–790.
Maroof, A.M., Keros, S., Tyson, J.A., Ying, S.W., Ganat, Y.M.,
Merkle, F.T., Liu, B., Goulburn, A., Stanley, E.G., Elefanty, A.G.,
et al. (2013). Directed differentiation and functional maturation
of cortical interneurons from human embryonic stem cells. Cell
Stem Cell 12, 559–572.
Marshall, H., Nonchev, S., Sham, M.H., Muchamore, I., Lumsden,
A., and Krumlauf, R. (1992). Retinoic acid alters hindbrain Hox
code and induces transformation of rhombomeres 2/3 into a 4/5
identity. Nature 360, 737–741.e Authors
Matsunaga, E., Araki, I., and Nakamura, H. (2001). Role of Pax3/7
in the tectum regionalization. Development 128, 4069–4077.
Mattis, V.B., and Svendsen, C.N. (2011). Induced pluripotent stem
cells: a new revolution for clinical neurology? Lancet Neurol. 10,
383–394.
Morrison, J.H., and Hof, P.R. (1997). Life and death of neurons in
the aging brain. Science 278, 412–419.
Moya, N., Cutts, J., Gaasterland, T., Willert, K., and Brafman, D.A.
(2014). EndogenousWNT signaling regulates hPSC-derived neural
progenitor cell heterogeneity and specifies their regional identity.
Stem Cell Reports 3, 1015–1028.
Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka,
T., Aoi, T., Okita, K., Mochiduki, Y., Takizawa, N., and Yamanaka,
S. (2008). Generation of induced pluripotent stem cells without
Myc from mouse and human fibroblasts. Nat. Biotechnol. 26,
101–106.
Nguyen, H.N., Byers, B., Cord, B., Shcheglovitov, A., Byrne, J.,
Gujar, P., Kee, K., Schu¨le, B., Dolmetsch, R.E., Langston, W., et al.
(2011). LRRK2 mutant iPSC-derived DA neurons demonstrate
increased susceptibility to oxidative stress. Cell Stem Cell 8,
267–280.
Nordstro¨m, U., Jessell, T.M., and Edlund, T. (2002). Progressive
induction of caudal neural character by graded Wnt signaling.
Nat. Neurosci. 5, 525–532.
Okada, Y., Shimazaki, T., Sobue, G., and Okano, H. (2004).
Retinoic-acid-concentration-dependent acquisition of neural cell
identity during in vitro differentiation of mouse embryonic stem
cells. Dev. Biol. 275, 124–142.
Okada, Y., Matsumoto, A., Shimazaki, T., Enoki, R., Koizumi, A.,
Ishii, S., Itoyama, Y., Sobue, G., and Okano, H. (2008). Spatiotem-
poral recapitulation of central nervous system development by
murine embryonic stem cell-derived neural stem/progenitor cells.
Stem Cells 26, 3086–3098.
Okano, H., and Yamanaka, S. (2014). iPS cell technologies: signifi-
cance and applications to CNS regeneration and disease. Mol.
Brain 7, 22.
Okuda, T., Haga, T., Kanai, Y., Endou, H., Ishihara, T., and Katsura,
I. (2000). Identification and characterization of the high-affinity
choline transporter. Nat. Neurosci. 3, 120–125.
Oliver, G., Mailhos, A., Wehr, R., Copeland, N.G., Jenkins, N.A.,
and Gruss, P. (1995). Six3, a murine homologue of the sine oculis
gene, demarcates the most anterior border of the developing neu-
ral plate and is expressed during eye development. Development
121, 4045–4055.
Osumi, N., Hirota, A., Ohuchi, H., Nakafuku, M., Iimura, T., Kura-
tani, S., Fujiwara, M., Noji, S., and Eto, K. (1997). Pax-6 is involved
in the specification of hindbrain motor neuron subtype. Develop-
ment 124, 2961–2972.
Porteus, M.H., Bulfone, A., Ciaranello, R.D., and Rubenstein, J.L.
(1991). Isolation and characterization of a novel cDNA clone
encoding a homeodomain that is developmentally regulated in
the ventral forebrain. Neuron 7, 221–229.
Poulsen, K.T., Armanini, M.P., Klein, R.D., Hynes, M.A., Phillips,
H.S., and Rosenthal, A. (1994). TGF beta 2 and TGF beta 3Stem Cell Repare potent survival factors for midbrain dopaminergic neurons.
Neuron 13, 1245–1252.
Qiu, M., Shimamura, K., Sussel, L., Chen, S., and Rubenstein, J.L.R.
(1998). Control of anteroposterior and dorsoventral domains of
Nkx-6.1 gene expression relative to other Nkx genes during verte-
brate CNS development. Mech. Dev. 72, 77–88.
Ring, D.B., Johnson, K.W., Henriksen, E.J., Nuss, J.M., Goff, D.,
Kinnick, T.R., Ma, S.T., Reeder, J.W., Samuels, I., Slabiak, T., et al.
(2003). Selective glycogen synthase kinase 3 inhibitors potentiate
insulin activation of glucose transport and utilization in vitro
and in vivo. Diabetes 52, 588–595.
Rogaev, E.I., Sherrington, R., Rogaeva, E.A., Levesque, G., Ikeda,
M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995).
Familial Alzheimer’s disease in kindreds with missense mutations
in a gene on chromosome 1 related to the Alzheimer’s disease
type 3 gene. Nature 376, 775–778.
Schwarz, M., Alvarez-Bolado, G., Dressler, G., Urba´nek, P.,
Busslinger, M., and Gruss, P. (1999). Pax2/5 and Pax6 subdivide
the early neural tube into three domains. Mech. Dev. 82, 29–39.
Sephton, C.F., Good, S.K., Atkin, S., Dewey, C.M., Mayer, P., 3rd,
Herz, J., and Yu, G. (2010). TDP-43 is a developmentally regulated
protein essential for early embryonic development. J. Biol. Chem.
285, 6826–6834.
Sherrington, R., Rogaev, E.I., Liang, Y., Rogaeva, E.A., Levesque, G.,
Ikeda,M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995). Cloning
of a gene bearing missense mutations in early-onset familial
Alzheimer’s disease. Nature 375, 754–760.
Shimamura, K., Hartigan, D.J., Martinez, S., Puelles, L., and Ruben-
stein, J.L. (1995). Longitudinal organization of the anterior neural
plate and neural tube. Development 121, 3923–3933.
Shimamura, K., Martinez, S., Puelles, L., and Rubenstein, J.L.
(1997). Patterns of gene expression in the neural plate and neural
tube subdivide the embryonic forebrain into transverse and longi-
tudinal domains. Dev. Neurosci. 19, 88–96.
Shimazaki, T., Shingo, T., andWeiss, S. (2001). The ciliary neurotro-
phic factor/leukemia inhibitory factor/gp130 receptor complex
operates in the maintenance of mammalian forebrain neural
stem cells. J. Neurosci. 21, 7642–7653.
Simeone, A., Acampora, D., Gulisano, M., Stornaiuolo, A., and
Boncinelli, E. (1992). Nested expression domains of four homeo-
box genes in developing rostral brain. Nature 358, 687–690.
Sinha, S., and Chen, J.K. (2006). Purmorphamine activates the
Hedgehog pathway by targeting Smoothened. Nat. Chem. Biol.
2, 29–30.
Suemori, H., Yasuchika, K., Hasegawa, K., Fujioka, T., Tsuneyoshi,
N., and Nakatsuji, N. (2006). Efficient establishment of human
embryonic stem cell lines and long-term maintenance with stable
karyotype by enzymatic bulk passage. Biochem. Biophys. Res.
Commun. 345, 926–932.
Swanson, D.J., Tong, Y., and Goldowitz, D. (2005). Disruption
of cerebellar granule cell development in the Pax6 mutant, Sey
mouse. Brain Res. Dev. Brain Res. 160, 176–193.
Takahashi, M., and Osumi, N. (2002). Pax6 regulates specification
of ventral neurone subtypes in the hindbrain by establishing pro-
genitor domains. Development 129, 1327–1338.orts j Vol. 5 j 1010–1022 j December 8, 2015 j ª2015 The Authors 1021
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., To-
moda, K., and Yamanaka, S. (2007). Induction of pluripotent stem
cells from adult human fibroblasts by defined factors. Cell 131,
861–872.
Thal, D.R., Ru¨b, U., Orantes, M., and Braak, H. (2002). Phases of A
beta-deposition in the humanbrain and its relevance for the devel-
opment of AD. Neurology 58, 1791–1800.
Turner, M.R., and Kiernan, M.C. (2012). Does interneuronal
dysfunction contribute to neurodegeneration in amyotrophic
lateral sclerosis? Amyotroph. Lateral Scler. 13, 245–250.
Walther, C., and Gruss, P. (1991). Pax-6, a murine paired box gene,
is expressed in the developingCNS.Development 113, 1435–1449.1022 Stem Cell Reports j Vol. 5 j 1010–1022 j December 8, 2015 j ª2015 ThXuan, S., Baptista, C.A., Balas, G., Tao, W., Soares, V.C., and Lai, E.
(1995). Winged helix transcription factor BF-1 is essential for
the development of the cerebral hemispheres. Neuron 14, 1141–
1152.
Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T.,
Yamanaka, S., Okano, H., and Suzuki, N. (2011). Modeling familial
Alzheimer’s disease with induced pluripotent stem cells. Hum.
Mol. Genet. 20, 4530–4539.
Yamasaki, T., Kawaji, K., Ono, K., Bito, H., Hirano, T., Osumi, N.,
and Kengaku, M. (2001). Pax6 regulates granule cell polarization
during parallel fiber formation in the developing cerebellum.
Development 128, 3133–3144.e Authors
